Development and novel therapeutics in hepatocellular carcinoma: a review

Pravinkumar Vishwanath Ingle
Sarah Zakiah Samsudin
Pei Qi Chan
Mei Kei Ng
Li Xuan Heng
Siu Ching Yap
Amy Siaw Hui Chai
Audrey San Ying Wong

Department of Pharmacy Practice, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia

Correspondence: Pravinkumar Vishwanath Ingle
Department of Pharmacy Practice, School of Pharmacy, International Medical University, No 126, Jalan Jalil Perkasa 19, 57000 Bukit Jalil, Wilayah Persekutuan, Kuala Lumpur, Malaysia
Tel +60 17 606 1709
Email pravinkumarvi@imu.edu.my

Abstract: This review summarizes the epidemiological trend, risk factors, prevention strategies such as vaccination, staging, current novel therapeutics, including the drugs under clinical trials, and future therapeutic trends for hepatocellular carcinoma (HCC). As HCC is the third most common cause of cancer-related death worldwide, its overall incidence remains alarmingly high in the developing world and is steadily rising across most of the developed and developing world. Over the past 15 years, the incidence of HCC has more than doubled and it increases with advancing age. Chronic infection with hepatitis B virus is the leading cause of HCC, closely followed by infection with hepatitis C virus. Other factors contributing to the development of HCC include alcohol abuse, tobacco smoking, and metabolic syndrome (including obesity, diabetes, and fatty liver disease). Treatment options have improved in the past few years, particularly with the approval of several molecular-targeted therapies. The researchers are actively pursuing novel therapeutic targets as well as predictive biomarker for treatment of HCC. Advances are being made in understanding the mechanisms underlying HCC, which in turn could lead to novel therapeutics. Nevertheless, there are many emerging agents still under clinical trials and yet to show promising results. Hence, future therapeutic options may include different combination of novel therapeutic interventions.

Keywords: hepatocellular carcinoma, HCC, novel therapeutics, treatment, management, molecular targeted therapies, clinical drug trial

Introduction

Hepatocellular carcinoma (HCC) is defined as the carcinoma emanating from the liver and also includes various underlying diseases. Globally, the cancer prevalence was reported to be 10.9 million per annum, and liver cancer came up as the sixth most common cancer with 749,000 cases and was ranked the third highest cause of cancer-related death with 692,000 mortalities per year. However, its geographical distribution is not uniform as shown in Figure 1. The highest HCC incidence occurs in resource-poor or developing countries such as sub-Saharan African, East Asia, and Melanesia, which covers 85% of reported global cases. Contrarily, incidence in developed countries is much lower, except in Southern Europe. To date, the mortality rate in the USA increased by 40% between the years of 1990 and 2004 as a result of hepatitis C virus (HCV) events.

Furthermore, HCC incidences increase with advancing age. The peak age for HCC incidence is at 70 years. However, peak age of incidence is less than 70 years in Chinese and black Africans. With regard to sex, it strikes males more than females, with a ratio of 2.4. Last decade, HCC mortality rose, particularly for male population in Austria, Denmark, Germany, Greece, Ireland, Portugal, Norway, Spain, Switzerland, and UK. This paper aims first at describing the current and future therapeutic trends in HCC management, second at identifying the preventative measures in lowering the
incidence of HCC, and finally at reviewing the progress in novel therapeutics in developing and developed regions.

Risk factors

These variations of risk factors link to etiology, complexity, and geographical distribution, particularly between developing and developed regions (Table 1).

Risk of HCC according to HBV genotype

Individuals with chronic hepatitis B virus (HBV) infection are at increased risk of developing end-stage liver disease (including cirrhosis, hepatic failure, and HCC), with a cumulative lifetime incidence of 15%–40%.11–13 Other important risk factors for HCC include the presence of HBV e-antigen – a surrogate marker of active viral replication – and the amount of HBV (ie, viral load) in serum.14,15

Several reports16–19 have also suggested that the genetic characteristics of HBV, including HBV genotype and specific genetic mutations, are associated with the development of HCC. Most of the recent studies suggest that the genetic characteristics of HBV, including HBV genotype and specific genetic mutations, are associated with the development of HCC.20–22

Table 1 The common risk factors in HCC

<table>
<thead>
<tr>
<th>No</th>
<th>Risk factor</th>
<th>Details</th>
<th>Regions</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>HBV</td>
<td>Inactivates tumor-suppressing genes</td>
<td>Africa, People’s Republic of China</td>
<td>1–3, 6</td>
</tr>
<tr>
<td>2</td>
<td>HCV</td>
<td>Immune response-mediated direct infection that leads to cirrhosis</td>
<td>USA, UK</td>
<td>1–3, 6</td>
</tr>
<tr>
<td>3</td>
<td>AFB₁</td>
<td>Contamination of staple foods by fungi Aspergillus flavus and Aspergillus parasiticus</td>
<td>Sub-Saharan Africa, Eastern Asia</td>
<td>1, 2, 8</td>
</tr>
<tr>
<td>4</td>
<td>Hemochomatosis</td>
<td>Leakage of stored iron to hepatocytes in iron excess more than 5 g</td>
<td>Africa</td>
<td>1, 2</td>
</tr>
<tr>
<td>5</td>
<td>HIV</td>
<td>Chronic viral hepatitis</td>
<td>USA</td>
<td>1, 3, 6–9</td>
</tr>
<tr>
<td>6</td>
<td>Metabolic syndromes (obesity, diabetes, fatty liver disease)</td>
<td>Increased waist circumstances, particularly BMI more than 30 kg/m²</td>
<td>USA</td>
<td>1–3, 6, 7, 10</td>
</tr>
<tr>
<td>7</td>
<td>Tobacco smoking</td>
<td>Smoking cumulatively 11,000 packs of cigarette during the lifetime increases the risk by 1.7-fold</td>
<td>USA</td>
<td>1, 2, 7, 10</td>
</tr>
<tr>
<td>8</td>
<td>Alcohol abuse</td>
<td>Excess of 80 g per day more than 10 years increases risk fivefold</td>
<td>USA, Europe</td>
<td>1, 7, 10</td>
</tr>
<tr>
<td>9</td>
<td>Mutation in germline DNA</td>
<td>Genetic predisposition to SNPs in EGF</td>
<td>USA</td>
<td>2</td>
</tr>
<tr>
<td>10</td>
<td>MOIVC</td>
<td>Obstruction of hepatic venous drainage by complete-clogged lesion</td>
<td>Africa</td>
<td>2</td>
</tr>
<tr>
<td>11</td>
<td>Oral contraception</td>
<td>Hepatocarcinogenic properties of oral contraception</td>
<td>USA</td>
<td>2</td>
</tr>
</tbody>
</table>

**Abbreviations:** HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; AFB₁, aflatoxin B1 exposure; SNPs, single nucleotide polymorphisms; EGF, epidermal growth factor; MOIVC, membranous obstruction of the inferior vena cava; BMI, body mass index.
Table 2 Child–Pugh classification of severity of liver disease

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Points assigned</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ascites</td>
<td>Absent</td>
</tr>
<tr>
<td>Bilirubin (mg/dL)</td>
<td>&lt;2</td>
</tr>
<tr>
<td>Albumin (g/dL)</td>
<td>&gt;3.5</td>
</tr>
<tr>
<td>Prothrombin time</td>
<td>Seconds over control</td>
</tr>
<tr>
<td>Encephalopathy</td>
<td>None</td>
</tr>
</tbody>
</table>

Notes: Stage of performance status: 0 = fully active; 1 = ambulatory and able to carry out light work; 2 = ambulatory but unable to carry out any work activities; 3 = capable of only limited self-care and confined to bed or chair; 4 = completely disabled.

Abbreviation: INR, international normalized ratio.

To date, HBV has been classified in to eight genotypes (A–H), according to intergroup divergence of 8% or more in the complete nucleotide sequence. Recent focus is on the clinically important differences in outcomes that are associated with the different HBV genotypes. The HBV genotypes have distinct geographical distributions and have been reported to have clinical relevance. For example, patients with genotypes C and D have a higher risk of disease progression and a poorer clinical outcome compared to the patients with genotypes A and B. Patients with genotypes A and B have a better response to IFN-based therapy than those with genotypes C and D. However, the association of genotypes B and C with HCC development remains controversial; some studies have shown that genotype C HBV infection is a risk factor for HCC, while others did not obtain the same results. The reason for these inconsistencies between the results, especially those derived from the same region, is unclear.

Staging

Introduction of various staging systems by different guidelines helps select the suitable interventions according to HCC classifications (Tables 2 and 3).

Table 3 BCLC staging

<table>
<thead>
<tr>
<th>BCLC stage</th>
<th>Types of HCC</th>
<th>Performance status</th>
<th>Tumor stage</th>
<th>Liver function status</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>Early HCC</td>
<td>0</td>
<td>Single, &lt;5 cm</td>
<td>No portal hypertension and normal bilirubin</td>
</tr>
<tr>
<td>A2</td>
<td>Early HCC</td>
<td>0</td>
<td>Single, &lt;5 cm</td>
<td>Portal hypertension and normal bilirubin</td>
</tr>
<tr>
<td>A3</td>
<td>Early HCC</td>
<td>0</td>
<td>Single, &lt;5 cm</td>
<td>Portal hypertension and abnormal bilirubin</td>
</tr>
<tr>
<td>A4</td>
<td>Early HCC</td>
<td>0</td>
<td>Three tumors, &lt;3 cm</td>
<td>Child–Pugh A–B</td>
</tr>
<tr>
<td>B</td>
<td>Intermediate HCC</td>
<td>0</td>
<td>Large multinodular</td>
<td>Child–Pugh A–B</td>
</tr>
<tr>
<td>C</td>
<td>Advance HCC</td>
<td>1–2</td>
<td>Vascular invasion/extrahepatic spread</td>
<td>Child–Pugh A–B</td>
</tr>
<tr>
<td>D</td>
<td>End-stage HCC</td>
<td>3–4</td>
<td>Any</td>
<td>Child–Pugh C</td>
</tr>
</tbody>
</table>

Notes: Grade A: 5–6 points (well-compensated disease); grade B: 7–9 points (significant functional compromise); grade C: 10–15 points (decompensated disease).

Abbreviations: BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma.

Management

Treatment

Resection

Resection is the first-line therapy for localized HCC without cirrhosis. Resection is not recommended in cirrhotic patients due to increased risk of perioperative decompensation. Nevertheless, resection is possible in cirrhotic patients whose liver transplantation (LT) is deemed to be unsuitable, provided that their hepatic function is well preserved.

Portal vein hypertension is regarded as an absolute contraindication to resection in EASL–EORTC Clinical Practice Guidelines. Studies demonstrated that the 5-year survival rate is only 30% regardless of the Child–Pugh score in the presence of portal vein hypertension and elevated bilirubin level, compared to 70% 5-year survival in patients with normal bilirubin level without portal vein hypertension. However, in other studies, it was also demonstrated that the presence of significant portal vein hypertension does not influence the outcomes of resection, even in cirrhotic patients.

Larger tumor is associated with higher risk of vascular invasion and dissemination. A cutoff of <2 cm was demonstrated as an independent predictor of survival rates in Japan, and the outcomes of each groups were 66% 5-year survival in <2 cm tumor group, 52% in 2–5 cm tumor group, and 37% in >5 cm tumor group after resection procedure.

Recurrence rate occurs up to 70% after 5 years is the main problem with resection. However, the evidence to demonstrate the effectiveness of initiating adjunct therapy after resection in preventing recurrence is not conclusive.

Liver transplantation

LT is the best curative therapy for candidates unsuitable to undergo liver resection as well as for patients with underlying...
cancer cells. However, survival rates as high as 70% have been recorded after chemoembolization.

Generally, LT can only be performed in patients in early stage of HCC. Milan criteria defined patients with single nodule <5 cm, or up to three separate nodules <3 cm, with no evidence of gross vascular invasion and no regional nodal or distant metastases. Using Milan criteria of patient selection, posttransplantation outcome with 5-year survival rates exceeds 70% (as shown in several studies). Nevertheless, shortage of donor livers has caused an unacceptably long transplant waiting time, resulting in waiting list exclusion when patients’ HCC progression extends beyond the transplantable criteria. The rate of waiting list exclusion may be as high as 25% if the waiting list is longer than 12 months. Model for End-stage Liver Disease score was therefore utilized to allocate the organ fairly according to priority.

Method
TACE involves catheterization of hepatic artery followed by injection of chemotherapy drugs (doxorubicin, mitomycin, and cisplatin) mixed with lipiodol and embolizing agents (gelatin or microspheres).

Chemoembolization with TACE-DEB
TACE-DEB is a new technique which delivers embolizing particles loaded with chemotherapeutic agent in the same manner as TACE.

Studies to prove effectiveness of chemoembolization
Studies have shown patients achieving 15%–55% partial responses and delay in tumor progression plus vascular invasion were noted. Moreover, median survival for patients increased from 16 to 20 months after chemoembolization.

In a Phase II trial, TACE-DEB with 150 mg doxorubicin achieved objective rates of 70% and insignificant systemic toxicity due to controlled elution over 1 week.

Note: Data taken from studies. Abbreviations:
TACE, transarterial chemoembolization; DEB, drug eluting beads.

**Table 4 Types of chemoembolization**

<table>
<thead>
<tr>
<th>Types of chemoembolization</th>
<th>TACE</th>
<th>Chemoembolization with TACE-DEB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Method</td>
<td>TACE involves catheterization of hepatic artery followed by injection of chemotherapy drugs (doxorubicin, mitomycin, and cisplatin) mixed with lipiodol and embolizing agents (gelatin or microspheres).</td>
<td></td>
</tr>
</tbody>
</table>
| Studies to prove effectiveness of chemoembolization | Studies have shown patients achieving 15%–55% partial responses and delay in tumor progression plus vascular invasion were noted. Moreover, median survival for patients increased from 16 to 20 months after chemoembolization. | In a Phase II trial, TACE-DEB with 150 mg doxorubicin achieved objective rates of 70% and insignificant systemic toxicity due to controlled elution over 1 week.
Table 5 Molecular-targeted therapies

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Types</th>
<th>Indication</th>
<th>Details of clinical trials</th>
<th>Side effects</th>
<th>Extra information</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sorafenib</td>
<td>Oral multi-tyrosine kinase inhibitor of VEGFR, platelet-derived growth factor receptor and Raf</td>
<td>Patients with well-preserved liver function and with advanced tumours/ those tumours progressing upon loco-regional therapies</td>
<td>Sorafenib HCC Assessment Randomized Protocol (SHARP) trial • Median overall survival: 10.7 months with sorafenib and 7.9 months with placebo • 31% decrease in relative risk of death • Median time to radiologic progression: 5.5 months with sorafenib and 2.8 months with placebo Phase III study in Asia • Overall survival: 6.5 months with sorafenib and 4.2 months with placebo</td>
<td>Hand-foot skin reactions (8%-16%) Diarrhea (8%-9%) Weight loss Hypophosphatemia Fatigue</td>
<td>Currently being tested • As an adjuvant after resection or complete local ablation for initial stages • In combination with chemoembolization for intermediate stages • In combination with Erlotinib/ systemic doxorubicin in advanced stages • As first line treatment for Child–Pugh B patients</td>
<td>50</td>
</tr>
<tr>
<td>Brivanib alaninate</td>
<td>Oral VEGFR and FGFR tyrosine kinase inhibitor</td>
<td>Phase II studies • Median overall survival: 10 months in first line patients with advanced tumor and 9.8 months in second line treated group Phase III studies • Median overall survival: 9.4 months with brivanib and 8.2 months with placebo • Median time to progression: 4.2 months for brivanib and 2.7 months for placebo</td>
<td>Hypertension (17%) Fatigue (13%) Hyponatraemia (11%) Decreased appetite (10%)</td>
<td>Currently being tested in three phase III clinical trials • First line blinded to sorafenib • Second line blinded to placebo • In combination with chemoembolization</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Bevacizumab</td>
<td>Recombinant, humanised monoclonal antibody against VEGF</td>
<td>Monotherapy • Median time to regression of 6.5 months • Objective responses of 10% With EGFR targeting agents • Median survival of 15 months for mixed HCC patient populations With chemotherapy (gemcitabine, oxaliplatin, capecitabine-based regimes) • Objective responses of 10–20% • Median survivals of 9–10 months</td>
<td>Approved for colorectal cancer, non-small cell lung cancer, and breast carcinoma treatment No phase III investigations</td>
<td>3, 51</td>
<td>3, 51, 52</td>
<td></td>
</tr>
<tr>
<td>Sunitinib</td>
<td>Multi-targeted tyrosine kinase inhibitor and PDGFR</td>
<td>Presently not recommended for treatment of HCC</td>
<td>• Used in phase II &amp; III clinical trials for HCC treatment Thrombocytopenia (29.7%) Neutropenia (25.7%) Bleeding (37.1%)</td>
<td>• Blockade of angiogenic receptors and reduces HCC development</td>
<td>3, 38, 51, 52</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Drugs</th>
<th>Types</th>
<th>Indication</th>
<th>Details of clinical trials</th>
<th>Side effects</th>
<th>Extra information</th>
<th>Reference</th>
</tr>
</thead>
</table>
| Erlotinib     | Tyrosine kinase inhibitor of the EGFR | Maintenance treatment of patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum-based, 1st line chemotherapy | • Phases I, I–II, II, III are under evaluation  
• Survival times of 15.6 months  
• Survival times of 6.8 months  
• Median of 13 and 6.3 months in 2 single-arm studies  
• Response rate of 25% and <10% in single-arm studies | Diarrhea led to dose reductions as a result of thrombocytopenia (6.7%), hand-foot syndrome (6.5%), and neutropenia (4.0%) | • GIST after disease progression on or intolerance to imatinib mesylate  
• Show anti-tumor activity in three phases II studies of patients with advanced HCC | 36, 52, 53 |
| Linifanib     | Tyrosine kinase inhibitor targeting PDGFR and VEGF |                                                                                   | • Phases II, III are under evaluation |                                                                                                                                  | • Being tested in phase III pivotal trials for regulatory approval | 38, 52    |
| Tivantinib    | Oral MET receptor tyrosine kinase inhibitor |                                                                                   |                                                                                                                                  |                                                                                                                                  | • Has synergistic effect against HCC when added to sorafenib  
• Used as a second-line agent for the treatment of HCC in previously unresectable HCC who progressed or could not tolerate first-line systemic therapy | 38        |
| Rapamycin (sirolimus) and its analogs (temsirolimus and everolimus) | Growth factors and proliferative pathway inhibitors (mTOR inhibitor) | Tested in preclinical and early clinical investigation |                                                                                                                                  |                                                                                                                                  | Everolimus  
• Used for kidney cancer therapy  
• Being tested in phase III for  
• a second line indication | 3         |
| Vatalanib, axitinib, cediranib | Anti-angiogenic | Being tested at early clinical investigation |                                                                                                                                  |                                                                                                                                  |                                                                 | 3         |

**Abbreviations:** US FDA, United States Food and Drug Administration; VEGFR, vascular endothelial growth factor receptor; FGFR, fibroblast growth factor; PDGFR, platelet derived growth factor receptor; Raf, rapidly accelerated fibrosarcoma; EGFR, epidermal growth factor receptor; VEGF, vascular endothelial growth factor; GIST, gastrointestinal stromal tumor; NSCLC, non-small cell lung cancer; HCC, hepatocellular carcinoma.
A meta-analysis of seven RCTs, including 898 patients, evaluated tamoxifen versus conservative management and showed neither antitumor effects nor survival benefits for tamoxifen. Subsequent large RCTs reported negative results in terms of survival. Cisplatin, IFN, doxorubicin, and fluorouracil (PIAF) used in combination showed promising activity in a Phase II study. A randomized Phase III study including 188 patients with HCC was conducted to investigate the effect of PIAF combination compared to doxorubicin alone. The median survival rate of the PIAF group did not significantly differ from the doxorubicin group (8.67 versus 6.83 months), and patients treated with the PIAF regimen experienced a significantly higher rate of myelotoxicity.

Prevention
Understanding risk factors of HCC supports the rationale for designing of prevention strategies, which aids in avoiding infection, chronic liver damage, and carcinogenesis process as well as early diagnosis of the disease and reduces the risk of recurrence.

Vaccination
HBV is attributable to more than 50% of the cases of HCC globally, it accounts for 15% of HCC in developed countries and 80%–90% of HCC in developing countries such as Asia and Africa. World Health Organization (WHO) introduced universal vaccination to all newborns and high-risk groups as routine immunization. Most of the studies showed that hepatitis B core antibody, hepatitis B surface antigen (HBsAg) carriers, HCC incidence, and HCC-related mortality were decreased following initiation of universal vaccination (Table 6).

Therapies stratified according to stage along with the treatment strategies and rational of HCC were summarized (Table 7).

Table 6 HBsAg carriers before and after initiate universal vaccination in high HBV prevalence countries

<table>
<thead>
<tr>
<th>High HBV prevalence countries</th>
<th>HBsAg carriers before and after initiate universal vaccination % (year)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taiwan (children aged &lt;15)</td>
<td>9.8 (1984) vs 4.0 (1994)</td>
<td>57</td>
</tr>
<tr>
<td>Gambia</td>
<td>10.0 (1986) vs 0.6 (1999)</td>
<td>58</td>
</tr>
<tr>
<td>Malaysia (children aged 7–12)</td>
<td>1.6 (1997) vs 0.3 (2003)</td>
<td>59</td>
</tr>
</tbody>
</table>

Abbreviations: HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus.

<table>
<thead>
<tr>
<th>Table 7 Therapies stratified according to stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage of HCC</td>
</tr>
<tr>
<td>Early-stage HCC</td>
</tr>
<tr>
<td>Intermediate-stage HCC</td>
</tr>
<tr>
<td>Advanced-stage HCC</td>
</tr>
</tbody>
</table>

Note: Data from studies.

Abbreviations: HCC, hepatocellular carcinoma; LT, liver transplantation.
risk reduction, while viral suppression also reverses cirrhosis, another risk factor of HCC development.\textsuperscript{56,67}

Oral nucleoside analogs (NAs) have been used to treat chronic hepatitis B.\textsuperscript{68} The use of first-generation NA is limited due to the development of resistance and virological relapse after treatment cessation.\textsuperscript{61} Newer generation NA with high antiviral and low drug-resistant potency, such as entecavir and tenofovir, are available.\textsuperscript{66,68} At the same time, combination therapy of pegylated IFN with ribavirin works well in preventing HCC development associated with HCV infection.\textsuperscript{68,69}

Survey
Survey is a diagnostic test applied periodically to patients at risk of developing a disease, aiming to reduce disease-related mortality through early diagnosis.\textsuperscript{3,35}

Serological and imaging tests are used in HCC surveillance, ultrasonography is the most widely used.\textsuperscript{3} Surveillance is mainly based on ultrasound examination as measuring alpha-fetoprotein levels, which is an example of serological test, has demonstrated inadequate sensitivity and specificity in recent studies.\textsuperscript{35}

Other preventive measures
WHO recommends implementation of an integrated and comprehensive strategy based on five key elements as listed in Table 8, aiming at preventing transfusion-transmitted HBV and HCV infection, especially in sub-Saharan African countries where there is relatively high risk of such mode of transmission. On the other hand, risky behaviors such as tattooing, body piercing, and unprotected sexual intercourse should be avoided to prevent transmission of HCV and HBV, along with implementation of related health policies by governmental health agencies (Table 9).\textsuperscript{3,35,70}

Discussion
Current novel therapeutics
Surgical intervention that includes liver resection and LT is the mainstay of treatment of HCC, but the selection criteria for

<table>
<thead>
<tr>
<th>Table 8 Categories of patients suitable for surveillance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Surveillance for HCC is recommended for the following categories of patients</strong></td>
</tr>
<tr>
<td>• Cirrhotic patients, Child–Pugh stage A and B.</td>
</tr>
<tr>
<td>• Cirrhotic patients, Child–Pugh stage C, waiting for LT.</td>
</tr>
<tr>
<td>• Noncirrhotic HBV carriers with active hepatitis or with family history of HCC.</td>
</tr>
<tr>
<td>• Noncirrhotic patients with chronic hepatitis C and bridging fibrosis.</td>
</tr>
<tr>
<td>• Chronic hepatitis B patients who remain at risk of HCC development.</td>
</tr>
<tr>
<td>• Patients with HCV-induced advanced fibrosis or cirrhosis, even after achieving sustained virological response.</td>
</tr>
</tbody>
</table>

Note: Data from study.\textsuperscript{3} 
Abbreviations: HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; LT, liver transplantation.

Table 9 Strategy to prevent transfusion-transmitted HBV and HCV infection by WHO

<table>
<thead>
<tr>
<th>Key elements</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Establish a nationally coordinated blood transfusion service</td>
</tr>
<tr>
<td>2 Collect blood from regular, voluntary, nonremunerated donors from low-risk populations</td>
</tr>
<tr>
<td>3 Test for transfusion-transmissible infections, blood group, and compatibility using quality-assured procedures</td>
</tr>
<tr>
<td>4 Reduce unnecessary transfusion through appropriate use of blood</td>
</tr>
<tr>
<td>5 Implement quality systems for the entire transfusion process, from donor recruitment to the follow-up of the recipients of transfusion</td>
</tr>
</tbody>
</table>

Note: Data taken from studies.\textsuperscript{71–75} 
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; WHO, World Health Organization.

both differ in different published clinical guidelines, resulting in difficulty in selecting the most appropriate therapy in treating HCC.\textsuperscript{74–79} Certain groups of patients who are defined to have well-preserved liver function and are deemed to be fit to undergo resection (Child–Pugh A score) may be regarded as not suitable for resection due to other circumstances such as the presence of portal vein hypertension.

Meanwhile, the gold standard in selecting patients for LT, Milan criteria, possesses some limitations that may exclude some of the potential patients.\textsuperscript{18} University of California at San Francisco criteria have been proposed, in which selection is based on having a single tumor nodule up to 6.5 cm or three or fewer tumors, the largest of which is <4.5 cm with the sum of the tumor diameters <8 cm.\textsuperscript{40} Its outcome is comparable to patients who are selected by using Milan criteria.\textsuperscript{40} Nevertheless, more studies should be conducted to confirm the validity of this extended criteria. However, it is still preferable to establish a standardized universal classification system in evaluating the liver status in patients with HCC to ensure the most appropriate option is selected for the patients, for both resection and LT procedure.

To date, sorafenib is the first and only available systemic therapy approved by FDA for treatment of HCC.\textsuperscript{3} Nevertheless, many emerging agents are still under clinical trials and yet to show promising results.\textsuperscript{51,81}

Future therapeutic trends
Living donor liver transplantation (LDLT) is proposed as it provides advantages to reduce the waiting time and increase the number of patients benefit from LT due to severe shortage of deceased donor livers. By comparing LDLT with deceased donor liver transplantation (DDLT), the waiting time is significantly shorter and dropout rate has reduced from 18% to 0%.\textsuperscript{40} However, it is still uncertain whether
the outcome of LDLT is equivalent or more favorable to that of DDLT.82

For tumors with size <2 cm and with the BCLC stage A, both PEI and RFA achieve complete responses in more than 90% of cases with good long-term outcome, which may substitute the roles of surgical intervention in early HCC in the future. In future, technical developments may achieve ablation areas of 5 cm or more in diameter, which will make percutaneous ablation an effective alternative to surgery even for tumors measuring 3 cm or more.38

Future therapeutic options may include different combination of novel therapeutic interventions. Combination of TACE-DEB has fewer complications than TACE due to slow release of chemotherapeutic drug.83 TACE-DEB was also better tolerated and significantly decreased liver toxicity and adverse effects and showed improved antitumor effect.34

There are also studies revealing the possibility of combination therapy of sorafenib with either TACE or radioembolization as both these combinations had demonstrated better therapeutic outcomes with improved overall survival and time to progression.3,39,83,84 More studies need to be conducted to examine this possibility as well as to solve the uncertainties regarding dose, frequency, and duration of sorafenib in combination therapy.

Universal vaccination is also one of the therapeutic interventions for HCC, especially in developing countries. A cost-effectiveness analysis by Hung and Chen84 demonstrated that universal vaccination shows high cost-effectiveness in reducing long-term sequelae of acute hepatitis B infection, HCC death, and chronic illnesses,3,39,83 which is further supported by another cost-effectiveness analysis by Hong et al85 in Vietnam.80

However, an effective prophylaxis vaccine for HCV is not yet available. Thus, preventing HCC is completely dependent on antiviral therapy for patients, until an effective vaccine is developed.68 Antiviral therapy with nucleotide analogs may be preferable than IFN treatment due to less adverse side effects and can be considered as a cost-effective adjuvant therapy for HCC after curative treatment.80 However, the exact role of antiviral treatment in preventing HBV-related HCC has been difficult to establish, due to the slow biological evolution of HBV.66

**Future technical aspect or extended indications for liver resection for HCC**

Recent improvement in surgical techniques and perioperative care has increased the safety and expanded the indication of hepatic resection for HCC to include large tumors that require extended hepatectomy in cirrhotic patients. Selection of appropriate candidates for hepatectomy depends on careful assessment of the tumor status and liver function reserve. Evaluation of the general fitness of patients is also critical because comorbid illness is an important cause of postoperative mortality, even if the patients have good liver function reserve. With careful patient selection and surgical expertise, the current operative mortality of hepatectomy for HCC is approximately 5% or less in major centers. Improved long-term survival results after resection of HCC have also been reported recently, with an overall 5-year survival rate of approximately 50%. The improved perioperative and long-term survival results have strengthened the role of hepatectomy as the mainstay of treatment for HCC despite the availability of a number of other treatment options for localized HCC.86

The main clinical advantage of laparoscopy for cirrhotic patients is probably the significantly lower rate of post-operative ascitic decompensation, which was reported in four comparative studies and three meta-analysis. This finding could be explained by the preservation of portosystemic venous collateral circulation around the liver and parietal abdominal wall, limited mobilization and manipulation of the liver, restricted fluid requirements, and decreased blood loss. Gaillard et al87 advocated that the positive pressure of the pneumoperitoneum might exert a tamponade effect on bleeding from intra-abdominal varices, which are a low-pressure system, thus decreasing blood loss. Lower blood transfusion requirement is also an advantage of the laparoscopic approach in this very risky group of patients.87

**Disclosure**

The authors report no conflicts of interests in this work.

**References**


